All In Biotech

Free tool

FAERS Monitor: Talzenna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217439 or its brand name (Talzenna, Talazoparib Tosylate). Reports on generic versions are filed under their own applications.

Reports

1,853

Serious

1,494

81% of reports

Hospitalization

632

Death reported

342

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia285
  • death194
  • neoplasm progression171
  • fatigue137
  • off label use101
  • thrombocytopenia100
  • haemoglobin decreased85
  • malignant neoplasm progression80
  • platelet count decreased79
  • febrile neutropenia71
  • pancytopenia71
  • nausea67
  • asthenia63
  • neutropenia63
  • dyspnoea50

Reports by year received

View as table
YearReports
20155
20162
201721
201829
2019210
2020202
2021154
2022199
2023252
2024239
2025336
2026204

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neoplasm progressionSignal17156.148.69,170
anaemiaSignal28517.015.34,304
pancytopeniaSignal7114.411.5876
febrile neutropeniaSignal7112.29.7718
thrombocytopeniaSignal10010.28.4820
haemoglobin decreasedSignal859.47.6633
malignant neoplasm progressionSignal808.97.2553
platelet count decreasedSignal798.46.8511
neutropeniaSignal635.34.1214
deathSignal1942.62.2190
fatigue1372.01.770
asthenia631.91.527
off label use1011.31.17
dyspnoea501.00.80
nausea671.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.